BPC 157 Side Effects Men Research
Share
BPC-157, a pentadecapeptide derived from human gastric juice, has been studied for its potential therapeutic benefits, particularly in wound healing and tissue repair. The side effects of BPC-157 in men, based on current preclinical and limited clinical data, appear to be minimal.
Preclinical studies have demonstrated that BPC-157 is well tolerated across various animal models, including mice, rats, rabbits, and dogs. These studies did not show any significant test-related adverse effects, even at higher doses. For instance, a study by Xu et al. reported that BPC-157 did not cause any serious toxicity, genetic, or embryo-fetal toxicity in these animal models.[1] Additionally, local tolerance tests indicated only mild irritation at the injection site.
In human studies, the safety profile of BPC-157 has also been favorable. A pilot study by Lee and Burgess assessed the safety of intravenous BPC-157 in two human participants. The study found no measurable adverse effects on biomarkers of the heart, liver, kidneys, thyroid, or blood glucose levels. Both participants tolerated the infusions well, with no reported side effects.[2] This suggests that BPC-157 is safe for intravenous administration in humans, although the sample size was very small.
Further supporting the safety profile, Sikiric et al. reviewed the use of BPC-157 in clinical trials for inflammatory bowel disease and wound healing. They reported no toxicity and no side effects in these trials, with the lethal dose (LD1) not being achieved.[3] This indicates a high safety margin for BPC-157.
Despite these promising findings, it is important to note that BPC-157 has not been approved by the FDA for use in standard medicine due to the lack of comprehensive clinical studies confirming its benefits and safety in humans.[4] The peptide was temporarily banned by the World Anti-Doping Agency (WADA) in 2022, although it is not currently listed as banned.[4]
In summary, the side effects of BPC-157 in men are generally mild and infrequent, based on available preclinical and limited clinical data. The most commonly reported side effects are mild injection site reactions. No serious adverse effects have been documented in the studies reviewed. However, the absence of extensive clinical trials means that the long-term safety profile of BPC-157 remains uncertain. Further research is needed to fully understand the potential risks and benefits of BPC-157 in human populations.
1. Preclinical Safety Evaluation of Body Protective Compound-157, a Potential Drug for Treating Various Wounds. Xu C, Sun L, Ren F, et al. Regulatory Toxicology and Pharmacology : RTP. 2020;114:104665. doi:10.1016/j.yrtph.2020.104665.
2. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
Lee E, Burgess K. Alternative Therapies in Health and Medicine. 2025;:AT11513. New Research
3. Toxicity by NSAIDs. Counteraction by Stable Gastric Pentadecapeptide BPC 157.
Sikiric P, Seiwerth S, Rucman R, et al. Current Pharmaceutical Design. 2013;19(1):76-83. doi:10.2174/13816128130111.
4. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Pharmaceuticals (Basel, Switzerland). 2025;18(2):185. doi:10.3390/ph18020185.